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DObjective: In the long-term, malignancy-associated thoracic radiation leads to varying degrees of pulmonary
fibrosis and radiation-associated cardiac disease, often requiring cardiothoracic surgery. We sought to determine
whether pulmonary fibrosis affects mortality in patients with radiation-associated cardiac disease undergoing
cardiothoracic surgery.
Methods: We studied 117 patients (aged 63  15 years, 71% were women) with radiation-associated cardiac
disease receiving multimodality imaging who underwent cardiothoracic surgery (21% redo) between 2000 and
2003. Some 50% of patients had breast cancer, 28% of patients had Hodgkin’s lymphoma, 9% of patients had
lung cancer, and 13% of patients had other cancers. Time from radiation was 18 12 years. Clinical, pulmonary
function, angiographic, and echocardiographic parameters were recorded. On multidetector chest computed
tomography, ascending aortic calcification and degree of pulmonary fibrosis (in 5 lobes for a score of 15:
0 ¼ none, 1 ¼ linear streaks, 2 ¼ moderate fibrosis, and 3 ¼ severe fibrosis with traction bronchiectasis)
were recorded.
Results: Mean European System for Cardiac Operative Risk Evaluation was 7.9  3, and forced expiratory
volume at 1 minute/forced vital capacity ratio was 0.75  0.2. Mean left ventricular ejection fraction was
49% 12%, and right systolic ventricular pressure was 42 5 mmHg. Some 27% of patients had severe aortic
stenosis, and 46% of patients had IIþ or greater mitral regurgitation. On multidetector chest computed
tomography, mean pulmonary fibrosis score was 3.5 3, and 59% of patients had ascending aortic calcification.
Isolated coronary artery bypass was performed in 17% of patients; the rest were combination surgeries.
At 6.3  0.4 years, there were 59 deaths (50%) (3% died 1 month postoperatively). Forty-five patients
(39%) had pulmonary complications in follow-up. Increasing pulmonary fibrosis score (hazard ratio, 1.11;
95% confidence interval, 1.02-1.20; P ¼ .02), worse European System for Cardiac Operative Risk Evaluation
(hazard ratio, 1.10; 95% confidence interval, 1.01-1.21; P ¼ .04), and lack of beta-blocker (hazard ratio,
0.54; 95% confidence interval, 0.31-0.94, P ¼ .008) and aspirin (hazard ratio, 0.54; 95% confidence interval,
0.31-0.94; P ¼ .03) independently predicted mortality.
Conclusions: In patients with radiation-associated cardiac disease undergoing cardiothoracic surgery,
worsening pulmonary fibrosis is associated with increasedmortality. (J Thorac Cardiovasc Surg 2014;148:475-81)Supplemental material is available online.
Thoracic radiation is an effective treatment for mediastinal
and thoracic cancers; however, cardiac disease is frequently
observed as a major cause of morbidity and mortality ine Heart and Vascular Institutea and Imaging Institute,b Cleveland Clinic,
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The Journal of Thoracic and Calong-term survivors.1-6 Although the exact prevalence of
radiation-associated cardiac disease (RACD) is difficult to
ascertain, studies have suggested that up to 42% of patients
will have significant asymptomatic valvular disease and
14% of patients will have myocardial ischemia1-3,7-11 in
the next couple of decades after radiation.6 The prevalence
of RACD is increasing because of maturation of the latent
period from the initial administration of chest radiotherapy,
which began in the late 1960s. The long-term cardiac effects
of radiation seem to be fairly heterogeneous with aggressive
coronary artery disease (especially ostial/proximal),
valvular disease (including significant, especially anterior
mitral annular thickening), pericardial disease (including
diffuse calcific constriction), advanced diastolic dysfunc-
tion, and conduction disease developing in patients.7-11
These patients often require cardiothoracic surgery (CTS),
and it is increasingly being recognized that such patientsrdiovascular Surgery c Volume 148, Number 2 475
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CTS ¼ cardiothoracic surgery
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
FEV1 ¼ forced expiratory volume at 1 minute
FVC ¼ forced vital capacity
HR ¼ hazard ratio
LV ¼ left ventricular
MDCT ¼ multidetector chest computed
tomography
PF ¼ pulmonary fibrosis
RACD ¼ radiation-associated cardiac disease
VTI ¼ velocity time integral
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Dhave a high degree of morbidity and mortality.2,3,5,12-15 In a
recent large cohort study, we have demonstrated that
patients with RACD have a significantly higher mortality
compared with a similarly matched control population
undergoing cardiac surgery.16 Furthermore, the primary
cause of mortality in that study was cardiopulmonary
failure during long-term follow-up.
In addition to peculiar echocardiographic features,16 a
characteristic pattern of pulmonary fibrosis (PF) also may
develop in patients with prior thoracic radiation,17 ranging
from linear fibrotic streaks to severe fibrosis and traction
bronchiectasis, especially in the regions that are exposed
to the radiation port (Figure E1). We sought to determine
the impact of the severity of PF on long-term mortality in
patients with RACD who underwent CTS.MATERIALS AND METHODS
Study Design
This was an observational study of 117 consecutive patients with RACD
who underwent CTS at the Heart and Vascular Institute and Imaging
Institute between 2000 and 2003 and had a multidetector chest computed
tomography (MDCT) scan and a resting echocardiogram performed in
close temporal association with the cardiac surgery (typically within 1
month preoperatively). All patients had a history of malignancy requiring
chest irradiation and as a result had subsequently developed coronary/
valvular disease requiring CTS. The diagnosis of RACD was made after
a thorough clinical and echocardiographic evaluation by experienced
cardiologists, based on characteristic findings, as described previously.16
In this group, type of prior malignancy and area of radiation were
ascertained. Where available, year of last radiation dose was recorded.
Also, the radiation dosages for various malignancies were recorded on
the basis of historic data. All patients were cancer-free at the time of cardiac
surgery.
Clinical Data
Data were assembled after appropriate approval by the institutional
review board. Demographics and clinical data were recorded prospectively
in the electronic health record. History and type of prior cardiac surgery476 The Journal of Thoracic and Cardiovascular Surgwere recorded. Use of medications at the time of initial presentation and
whether they were initiated in the postoperative period were recorded.
Presence of permanent atrial fibrillation (defined according to guidelines18)
was ascertained at baseline and at the time of discharge. Presence of an
automated implantable cardioverter defibrillator and need for permanent
pacemaker were recorded. From spirometry and pulmonary function
testing, we recorded forced vital capacity (FVC) and forced expiratory
volume at 1 minute (FEV1) data. We calculated FEV1/FVC ratio.
We also recorded the extent of any pulmonary complications during
follow-up, dividing them as follows: simple (recurrent pleurocentesis,
home oxygen use) and major (prolonged intubation with resultant
tracheostomy and pleurodesis/decortication).
The details of cardiac surgery were recorded and categorized as follows:
(1) coronary artery bypass grafting (CABG); (2) CABG þ 1-valve repair/
replacement; (3) CABG þ 2-valve repair/replacement; (4) 1-valve
repair/replacement; (5) 2-valve repair/replacement; and (6) others,
including pericardiectomy, transplantation, left ventricular (LV) assist
device, aortic surgery, and myectomy. In patients who underwent CABG,
the number of bypassed vessels was recorded. On the basis of the available
preoperative data, additive euroSCOREwas calculated to predict the risk of
postoperative mortality.19
Follow-up
The beginning of follow-up was considered as the date of cardiac
surgery at our institution. Death notification was obtained from the medical
record or the US Social Security Death Index database, and survival was
ascertained during follow-up (last query was in March 2011). Where
available, cause of death was ascertained. Postoperative stroke was defined
as transient or permanent neurologic impairment and disability due to
vascular causes, including episodes lasting less than 24 hours, which
were regarded as transient ischemic attacks.
Echocardiography
All patients underwent a comprehensive transthoracic echocardiogram
using commercial instruments (Philips Medical Systems, NA, Bothell,
Wash; General Electric Medical Systems, Milwaukee, Wis; and
Siemens Medical Solutions USA, Inc, Malvern, Pa) as part of standard
clinical diagnostic and pre-open surgery workup. Standard parameters were
assessed according to standard guidelines and recorded prospectively.20-23
Degree of mitral, aortic, and tricuspid regurgitation were assessed on a
scale of 0 to 4þ (0¼ none, 1 þ ¼ mild, 2þ ¼ moderate, 3þ ¼ moderately
severe, and 4þ ¼ severe). Right ventricular systolic pressure was recorded
from tricuspid regurgitation velocity and estimated right atrial pressure.
Peak/mean transvalvular gradients, velocity time integrals (VTIs) across
valves/LV outflow tract, and diameter of LV outflow tract were recorded.
Aortic valve area was calculated using continuity equation, and aortic
stenosis was graded in a standard fashion. Dimensionless index (LVoutflow
tract VTI/aortic VTI) was calculated. Postoperative transthoracic
echocardiography was performed as described earlier.
Chest Multidetector Computed Tomography
Cardiothoracic MDCT angiographic studies were performed using
standard scanners available at the time (Siemens Medical Systems,
Erlangen, Germany) using the following parameters: nongated spiral
imaging, 750 to 850mAs, 120 kV, and 1-mm slice thickness. In 72 patients,
at the discretion of the referring physicians, no iodinated contrast was
administered. In the remaining 45 patients, 90 mL isosmolar contrast
was administered, with use of peak enhancement in the aortic root for
timing of the scan. Over the years, the scan parameters generally remained
similar despite scanner upgrades. All images were acquired during an
inspiratory breath hold of 10 to 20 seconds.
Two independent readers with experience in interpretation of chest
computed tomography (MD and KK) scored the degree of PF, on aery c August 2014
FIGURE 1. HRs for long-term mortality in patients with RACD plotted
against mean PF score divided into 5 equal quintiles. All comparisons
have been derived using Cox proportional hazard regression model using
the first decile as the reference category.
TABLE 1. Clinical characteristics of the study population
Variable (n ¼ 117)
Age 63  15 y
Female gender 83 (71%)
Hypertension 48 (41%)
Diabetes mellitus 19 (16%)
Prior stroke 10 (9%)
Smoking history 43 (37%)
Proximal obstructive coronary artery disease 53 (45%)
Prior open surgery 24 (21%)
Implantable cardioverter defibrillator 7 (6%)
FVC (mL) 2.1  0.9
% predicted FVC 66  22
FEV1 1.6  0.6
FEV1/FVC ratio 0.75  0.2
euroSCORE 7.9  3
Beta-blockers 75 (64%)
ACE inhibitors 42 (36%)
Aspirin 64 (55%)
Statins 38 (32%)
Hemoglobin (mg/dL) 14  1.0
Creatinine (mg/dL) 0.98  0.5
Total cholesterol 179  44
Low-density lipoprotein 99  37
Triglycerides 144  85
High-density lipoprotein 52  17
Type of CTS
CABG 20 (17%)
CABG þ 1 valve 20 (17%)
CABG þ 2 valve 28 (24%)
1 valve only 22 (19%)
2 valves 21 (18%)
Others 6 (5%)
No. of bypass grafts 1.3  1.4
ACE, Angiotensin-converting enzyme; CABG, coronary artery bypass grafting;
CTS, cardiothoracic surgery; euroSCORE, European System for Cardiac Operative
Risk Evaluation; FEV1, forced expiratory volume at 1 minute; FVC, forced vital
capacity.
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of previously published x-ray criteria17: 0 ¼ none, 1 ¼ linear streaks,
2 ¼ moderate fibrosis, and 3 ¼ severe fibrosis with traction bronchiec-
tasis (Figure E1). With the use of this scale, all 5 lobes of the lungs
were scored, with a maximum score of 15. The presence of ascending
aortic calcification was ascertained and semiquantitatively scored as
follows: none, mild (less than half of the circumference), moderate
(half the circumference), and severe (more than half circumference). A
detailed assessment of cardiac morphology (including coronaries and
bypass grafts) was not the clinical focus; thus, the scans were not
dedicated for their assessment. However, we did record the presence of
high-risk features in patients undergoing redo cardiac surgery, as
previously described: bypass grafts crossing midline less than 1 cm
from the sternum, right-sided cardiac structures, and ascending aorta
tethered to chest wall.24
Statistical Analysis
Continuous variables were expressed as mean  standard deviation
or median. Categoric data are presented as percentage frequency.
Differences between groups were compared with the use of the Student t
test or analysis of variance (for parametric variables) and the Mann–Whit-
ney test (for nonparametric variables) for continuous variables. Chi-square
test was used for categoric variables. Linear regression between continuous
variables was tested using the Pearson correlation coefficient. Cumulative
event rates as a function over time were obtained by the Kaplan–Meier
method, and curves of mortality were compared using log-rank test. A uni-
variable and multivariable Cox proportional hazards model was developed
to determine the independent predictors of mortality. As a first step, uni-
variable predictors were assessed individually using bootstrapping (to in-
crease reliable assessment of risk factors by improving the precision of
estimate), and a total of 1000 bootstrapped models were generated.
Variables that entered the model at least 75 times were considered
significant. Subsequently, stepwise multivariable regression analysis was
performed, and the variables with a P value less than .05 remained as inde-
pendent predictors. The final univariate and multivariate results are repre-
sented by hazard ratios (HRs) and their 95% confidence intervals (CIs). To
establish a cutoff above which the PF score was associated with a signifi-
cant increase in mortality, we divided the score into quintiles. We subse-
quently conducted Cox survival analysis incorporating the PF score
quintiles as an independent covariate. Statistical analysis was performed
using SPSS version 11.5 (SPSS Inc, Chicago, Ill).The Journal of Thoracic and CaRESULTS
Clinical Characteristics
The baseline characteristics of the study population are
shown in Table 1. This was a relatively young population
with an average distribution of known cardiovascular risk
factors. All patients had advanced symptoms necessitating
cardiac surgery. No patient had advanced disease on
pulmonary function testing to preclude surgery. In the
group, 36 patients (31%) had significant reduction in preop-
erative glomerular filtration rate (<60 mL/min/1.73 m2).
The distribution of prior malignancies and average radiation
doses were as follows: 59 (50%) breast cancers (55 Gy),
9 (8%) lung cancers (60 Gy), 33 (28%) Hodgkin’s
lymphomas (45 gray), 6 (5%) non–Hodgkin’s lymphomas
(45 Gy), and 10 (9%) others (thymoma, testicular, and
thyroid cancers, 45 Gy). No patient had a known recurrence
of malignancy at the time of cardiac surgery. The meanrdiovascular Surgery c Volume 148, Number 2 477
TABLE 2. Baseline imaging characteristics of the study population
Variable N ¼ 117
Preoperative echocardiography
LV ejection fraction 49%  12%
LV end-diastolic dimension 4.5  0.8 cm
LV end-systolic dimension 3.2  1.0 cm
Left atrial dimension 3.9  0.8 cm
Diastolic dysfunction
Abnormal relaxation 56 (48%)
Pseudonormal 16 (14%)
Restrictive filling 10 (9%)
Mitral regurgitation (IIþ) 54 (46%)
Mitral valve splitability score (of 16) 5  4
Aortic regurgitation (IIþ) 41 (35%)
Dimensionless index for aortic valve 0.41  0.2
Severe aortic stenosis 32 (27%)
Tricuspid regurgitation (IIþ) 50 (43%)
Right ventricular systolic pressure 42  5 mm Hg
Preoperative CT
Moderate or more emphysema 0
PF score 3.5  3
Ascending aortic calcification 69 (59%)
Ascending aortic calcification
None 48 (41%)
Mild (<1/2 circumference) 36 (31%)
Moderate (1/2 circumference) 18 (15%)
Severe (circumferential) 15 (13%)
CT, Computed tomography; LV, left ventricular; PF, pulmonary fibrosis.
TABLE 3. Stepwisemultivariable Cox proportional hazard predictors
of mortality in the study population
Variable Hazard ratio (95% CI) P value
Beta-blockers 0.47 (0.26-0.83) .008
Aspirin 0.54 (0.31-0.94) .03
euroSCORE 1.10 (1.01-1.21) .04
PF score on MDCT 1.11 (1.02-1.20) .02
Overall chi-square of the model: 27, P<.001. Because age and creatinine are part of
the euroSCORE, they were not included in the final multivariable analysis. Dimen-
sionless index and FEV1/FVC ratio did not remain significant on stepwise multivari-
able analysis. CI, Confidence interval; euroSCORE, European System for Cardiac
Operative Risk Evaluation; MDCT, multidetector chest computed tomography;
PF, pulmonary fibrosis.
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radiation was 18  12 years.Imaging Characteristics
The baseline echocardiographic characteristics of the
study population are shown in Table 2. In the study
population, the distribution of LV ejection fraction was as
follows: 69 patients (59%) with ejection fraction 55% or
greater, 36 patients (31%) with ejection fraction between
30% and 55%, and 12 patients (10%) with ejection fraction
less than 30%. As shown in Table 2, there was a high
prevalence of valvular heart disease.
MDCT characteristics are shown in Table 2. In the study
population, 20 patients (17%) had no evidence of PF, and
35 patients (30%) had a PF score of 1 or 2 (mild). The
remainder had significant pulmonary fibrotic changes.
There was a modest correlation between the PF score and
the time of last chest radiation (r ¼ 0.29, P<.01). There
was no significant association between radiation dose and
degree of PF in the study population (r ¼ 0.10, P ¼ not
significant). As expected, there was an inverse correlation
between PF score and FVC on pulmonary function testing
(r ¼ 0.31, P<.01). There was only a modest correlation
between European System for Cardiac Operative Risk
Evaluation (euroSCORE) and PF score (r ¼ 0.16,
P ¼ .07). The assessment of degree of PF in the study478 The Journal of Thoracic and Cardiovascular Surgpopulation had good interobserver and intraobserver
reproducibility: Intraclass correlation coefficients were
0.90 (0.76-0.96) and 0.92 (0.81-0.96), respectively
(both P<.001).
Ascending aortic calcification was noted in 69 patients
(60%), with 15 (13%) having a porcelain aorta. The
majority of patients with a history of redo cardiac surgery
had tethering of right-sided cardiac structures to the chest
wall (95%), and 5 patients had CABG crossing midline
less than 1 cm behind the sternum.Outcomes
The clinical and echocardiographic results in the
postoperative period for the entire study population are
shown in Table E1. Relevant baseline and postoperative
findings in the study population, divided according to
high or low PF score, are shown in Table E2. As shown
in Table E3, during a mean postoperative follow-up of
6.3  4 years, a high proportion of patients in the study
population had pulmonary complications (39% with any
and 19% with major complications). The proportion of
patients with pulmonary complications was higher in
the group with a PF score of 3 or greater versus the group
with a PF score less than 3 (Table E2). This was despite
similar euroSCORES: (1) any pulmonary complications
versus no pulmonary complications (8  3 vs 7.8  3,
P ¼ .7) and (2) major pulmonary complications (7.6  4
vs 7.9  3, P ¼ .7). During follow-up, a high proportion
of patients in the study population died (n ¼ 59 [50%]).
One-month mortality was low and occurred in only 4 pa-
tients (3%). However, an additional 13 patients (8%) died
in the first year. The cause of death was ascertained to be
cardiopulmonary disease in 55 patients (49%) and recurrent
malignancy in 5 patients (5%). In the remaining patients,
the cause of death could not be definitively ascertained.
As expected, therewas higher mortality in patients with pul-
monary complications versus no pulmonary complications:
any (29 [64%] vs 16 [36%], P ¼ .01) and major complica-
tions (15 [71%] vs 6 [29%], P ¼ .03).
Subsequently,weperformedunivariable and stepwisemulti-
variable Cox proportional hazard analysis (Tables E3 and 3).ery c August 2014
FIGURE 2. Kaplan–Meier curve analysis demonstrating significant
differences in long-term mortality in patients with RACD, divided into
4 subgroups, based on medians of euroSCORE and PF score (see text for
details). euroSCORE, European System for Cardiac Operative Risk Evalu-
ation; PF, pulmonary fibrosis.
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established cardioprotective medications (beta-blockers and
aspirin) were associated with significantly reduced survival.
Severity of aortic stenosis and lower FEV1/FVC ratio,
although predicting worse mortality on univariable analysis,
did not remain significant on stepwise multivariable analysis.
In the subgroup undergoing redo CTS, no patient had injury
to cardiac structures at the time of median sternotomy.
Medians of euroSCORE and PF score were generated,
and Kaplan–Meier survival analysis was performed
(Figures E2 and E3). On the basis of PF quintiles,
we subsequently conducted Cox survival analysis
incorporating it as an independent covariate. Figure 1 dem-
onstrates the HRs for mortality plotted against mean PF
score within that quintile. All comparisons were derived us-
ing the first quintile as the reference category. It
demonstrates that a PF score of 6 or greater was
significantly predictive of mortality independently of
euroSCORE, age, and gender. Finally, to understand the
interplay between PF and euroSCORE, we further divided
the patients into 4 subgroups as follows: (1) both below
median (n ¼ 30); (2) PF score above median, euroSCORE
below median (n ¼ 23); (3) PF score below median,
euroSCORE above median (n ¼ 24); and (4) both above
median (n ¼ 40). During the follow-up, the distribution of
mortality in these subgroups was 8 (27%), 11 (46%), 11
(48%), and 29 (73%), respectively (P<.001). The survival
curves of these 4 subgroups are shown in Figure 2.DISCUSSION
In the current study of patients with RACD who
underwent complex CTS after a multimodality imaging
evaluation (including MDCT and echocardiography), weThe Journal of Thoracic and Cademonstrate that increasing degree of PF, assessed on
preoperative MDCT, was a significant predictor of worse
long-term mortality independently of euroSCORE. None
of the standard echocardiographic variables independently
predicted outcomes on multivariable survival analysis.
Low dimensionless index (suggesting worse aortic stenosis)
and FEV1/FVC ratio were associated with mortality on
univariable analysis, but not on multivariable analysis.
Although the degree or presence of ascending aortic
calcification did not provide incremental predictive value
for mortality, the stroke rate at 30 days was 0%. In the
current cohort of patients in whom MDCT was performed,
requiring a redo cardiac procedure was not associated with
increased mortality, with no reported bypass graft or cardiac
structure injuries. This goes along with previous studies
that have demonstrated the use of thoracic MDCT,
before redo cardiac surgery, helps reduce postoperative
complications.24
As demonstrated previously, patients with RACD have a
significantly higher mortality compared with an age-
and gender-controlled population undergoing similar
types of cardiac surgical procedures, despite similar
euroSCORES.16 The majority of these patients died of
cardiorespiratory causes, as opposed to recurrent
malignancies. A high proportion of patients had residual
pulmonary complications (including 18% requiring
tracheostomy or pleurodesis/pleural decortication), and
patients with pulmonary complications during follow-up
were more likely to die. There was a significant association
between PF, seen on preoperativeMDCT, and postoperative
pulmonary complications. Thus, there needs to be
increased awareness of prior thoracic radiation, including
characteristic pattern recognition on imaging studies. The
current study also highlights that in RACD, prediction of
mortality, solely based on standard preoperative scores,
can be suboptimal. On the basis of the euroSCORE, the
study population would have been deemed at intermediate
risk with an expected mortality of approximately 3%
to 5%.19,25 Thus, it seems that additional imaging
evaluation, including assessment for pulmonary fibrotic
changes on MDCT (Figure 2), is potentially useful and
could provide incremental value in terms of risk prediction.
For these complex patients, we need to develop a more
appropriate diagnostic algorithm that incorporates findings
on multimodality imaging.
Radiotherapy administered for thoracic malignancy
results in a characteristic bimodal pattern of pulmonary
damage: initial radiation pneumonitis (in5%-15% cases)
occurring early in the first 2 to 3 months, followed by PF,
typically occurring after 3 months.26,27 Because MDCT
scans in the current study were performed many years
after chest radiotherapy, only PF changes were visualized.
It has been shown that PF seldom occurs when the
radiation dose is less than 20 Gy, but highly likely whenrdiovascular Surgery c Volume 148, Number 2 479
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modest but significant association between degree of PF and
time from last radiation. PF occurs as a consequence of the
repair process after acute tissue injury.28 Thoracic radiation
and resultant PF can lead to symptoms due to reduction in
FVC and diffusing capacity.29-31 A significantly higher
proportion of patients with advanced PF had postoperative
pulmonary complications and, in turn, increased
mortality. It is conceivable that there is progressive
pleural fibrosis and recurrent pleural effusions, both of
which tend to be exacerbated further during cardiac
surgery, resulting in additional deterioration of pulmonary
function. Given these findings, it is important to anticipate
and attempt to minimize these problems. On a preventive
note, with increasing understanding of the deleterious
long-term effects of radiotherapy for thoracic malignancies,
every effort should be made to minimize exposure of the
lungs and heart with the use of appropriate radiation shield-
ing. However, in cases of somemalignancies, such as Hodg-
kin’s or non–Hodgkin’s lymphoma, extensive mediastinal
involvement might make cardiac shielding impossible. Pre-
vious studies also have evaluated the role of various medical
therapies, including angiotensin-converting enzyme inhibi-
tors and combined tocopherol/pentoxifylline in regression
of radiation-induced fibrosis, with promising results.32,33
However, these findings need further validation in large-
scale human studies.
Previous reports have demonstrated various predictors of
short-term mortality (constrictive pericarditis, reduced
preoperative ejection fraction, longer cardiopulmonary
bypass times) and long-term mortality (radiation dose,
duration of radiation).1-3 However, these studies had
significantly smaller sample sizes, and patients with
complex surgeries (eg, CABG þ valve procedures) were
excluded. Chang and colleagues5 demonstrated that
extensive radiation (as opposed to tangential exposure)
was associated with worse survival. In all these studies,
comprehensive multimodality imaging was not used. This
is the largest study to systematically assess the incremental
prognostic utility of multimodality imaging characteristics
on long-term mortality in this high-risk population.
Clinical Implications and Future Outlook
From a management perspective, given the high
complexity in patients with RACD, it seems appropriate
to carefully characterize these patients using clinical
(including detailed pulmonary function testing) and
multimodality imaging (echocardiography and, in selected
cases, MDCT). On the basis of the current study, it seems
that a PF score of 6 or greater is associated with a significant
increase in mortality. As a result, once a high-risk substrate
has been identified, it might be prudent to examine
other treatment options, such as percutaneous intervention
for coronary artery disease or transcatheter aortic valve480 The Journal of Thoracic and Cardiovascular Surgreplacement.34,35 Another consideration is heart
transplantation or heart lung transplantation in selected
patients. However, this approach has potentially
significant additional issues, such as recurrent
malignancy. In addition, the effect of radiation on the
pulmonary vasculature and thoracic volume may render
lung transplantation difficult or even impossible. In
patients with documented PF, strategies to reduce
pulmonary damage during cardiac surgery should be
incorporated. Further research in the field of optimizing
lung function preoperatively (eg, preemptive pulmonary
rehabilitation) is needed.
Study Limitations
This was an observational study with potential tertiary-
care referral bias; thus, the data are not generalizable to
all patients with a history of thoracic radiation. Because
the majority of these patients were referred long after
their initial cancer diagnosis, comprehensive data on
radiation dose and chemotherapeutic regimen (especially
doxorubicin [Adriamycin; Bedford Laboratories, Bedford,
Ohio]/bleomycin, which could affect PF) were not
available. However, we did incorporate radiation doses
that were prevalent at the time of their initial cancer
diagnosis into our analysis. During the time frame that the
patients with RACD were evaluated and underwent
operation at our institution, performing MDCT was not a
clinical routine. As a result, the sample size of patients
undergoing a complete multimodality imaging evaluation
was smaller than those with RACD undergoing surgery.
Semiquantitative PF assessment by MDCT is not
standardized. Comprehensive pulmonary function testing
data (especially diffusing capacity) were not always
performed and thus are not reported. Advanced echo-
cardiography indices, including tissue Doppler and strain
analysis, was not available at the time of surgery. Data on
cancer recurrence during post-radiotherapy follow-up
(at the site of radiation or a remote site) were not uniformly
available. However, all patients were free of malignancy at
the time of cardiac surgery. Cardiopulmonary bypass times
were not available as part of electronic health records;
however, it is conceivable that they were higher in these
high-risk complex cases. We chose all-cause mortality
because it is more relevant in the current population.
CONCLUSIONS
Worsening degree of PF in patients with RACD undergo-
ing CTS is associated with significantly worse long-term
outcomes independently of standard preoperative risk
stratification. A dedicated multifaceted diagnostic approach
(including echocardiography, chest MDCT, and pulmonary
function testing) should be adopted to carefully evaluate
these patients preoperatively. Once a high-risk substrate is
identified, alternative treatment options might be worthery c August 2014
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Dexploring. However, further research is needed in these
high-risk patients.
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FIGURE E1. MDCT scans in patients with varying degrees of PF: none-minimal (A), moderate (B), and severe (C) (see text for details).
FIGURE E2. Kaplan–Meier curve analysis demonstrating significant
differences in long-term mortality in patients with RACD who underwent
cardiac surgery, separated on the basis of median euroSCORE
(median ¼ 8). euroSCORE, European System for Cardiac Operative Risk
Evaluation.
FIGURE E3. Kaplan–Meier curve analysis demonstrating significant dif-
ferences in long-termmortality in patients with RACDwho underwent car-
diac surgery, separated on the basis of themedian of PF score (median¼ 3).
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TABLE E1. Postoperative findings in the study population
Variable N ¼ 117
Clinical postoperative characteristics
Perioperative length of stay 17  40 d
Perioperative intensive care unit length of stay 5  10 d
Postoperative permanent atrial fibrillation 19 (16%)
Postoperative permanent pacemaker 12 (10%)
Postoperative stroke 0
Postoperative pulmonary complications (any) 45 (39%)
Postoperative pulmonary complications (major) 21 (18%)
Pre-discharge echocardiography
LV ejection fraction (%) 46  14
At least mild right ventricular dysfunction 34 (29%)
Mitral regurgitation (IIþ) 11 (9%)
Aortic regurgitation (IIþ) 3 (3%)
Tricuspid regurgitation (IIþ) 36 (31%)
Right ventricular systolic pressure 35  9 mm Hg
LV, Left ventricular.
TABLE E2. Relevant clinical and imaging characteristics of study population, separated on the basis of pulmonary fibrosis score
Variable PF score<3 (n ¼ 55) PF score 3 (n ¼ 62) P value
Age (y) 65  11 62  15 .3
Female gender 42 (76%) 41 (66%) .2
Hypertension 25 (47%) 23 (37%) .2
Diabetes mellitus 6 (11%) 13 (%) .13
Prior stroke 4 (8%) 6 (10%) .5
Smoking history 4 (8%) 15 (24%) .02
Proximal obstructive CAD 27 (49%) 26 (42%) .3
Prior open surgery 9 (16%) 15 (24%) .2
FVC (mL) 2.5  0.8 1.8  0.8 .002
% Predicted FVC 77  20 57  20 .001
FEV1 1.8  0.6 1.4  0.6 .004
FEV1/FVC ratio 0.75  0.2 0.75  0.1 .9
euroSCORE 7.1  3 9  3 .01
Type of CTS
CABG 15 (27%) 5 (8%)
CABG þ 1 valve 12 (22%) 8 (13%)
CABG þ 2 valve 10 (18%) 18 (29%)
1 valve only 8 (15%) 14 (23%)
2 valves 8 (15%) 13 (21%)
Others 2 (4%) 4 (7%) .04
In-hospital length of stay (d) 15  13 19  15 .2
Intensive care unit stay (d) 3  5 6  5 .2
Preoperative LVEF (%) 50  13 49  13 .6
Preoperative RVSP (mm Hg) 40  16 45  13 .2
Postoperative RVSP (mm Hg) 33  9 36  10 .2
Postoperative RV dysfunction 5 (9%) 22 (35%) .3
Postoperative pulmonary complications (any) 14 (26%) 31 (50%) .005
Postoperative pulmonary complications (major) 5 (9%) 16 (26%) .02
CABG, Coronary artery bypass grafting; CAD, coronary artery disease; CTS, cardiothoracic surgery; euroSCORE, European System for Cardiac Operative Risk Evaluation;
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; PF, pulmonary fibrosis; RV, right ventricular; RVSP, right
ventricular systolic pressure.
Desai et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 148, Number 2 481.e2
A
C
D
TABLE E3. Univariable Cox proportional hazard predictors of
mortality in the study population
Variable
Hazard ratio
(95% CI)
P
value
Preoperative findings
Age 1.02 (0.99-1.02) .08
Gender 0.74 (0.41-1.33) .3
Hypertension 1.12 (0.65-1.94) .7
Diabetes mellitus 1.21 (0.71-2.07) .5
Hyperlipidemia 0.75 (0.40-1.30) .3
Prior stroke 1.88 (0.73-4.81) .12
Proximal obstructive coronary disease 1.20 (0.70-2.06) .5
Implantable defibrillator 1.02 (0.36-2.87) .9
Permanent pacemaker 1.43 (0.77-2.66) .3
Type of prior cancer 1.05 (0.96-1.15) .3
Prior radiotherapy dose for cancer 0.98 (0.95-1.02) .4
Prior open surgery 0.98 (0.53-1.78) .4
Type of cardiac surgery performed 1.12 (0.94-1.34) .2
euroSCORE 1.14 (1.04-1.26) .005
Beta-blockers 0.49 (0.29-0.82) .006
ACE inhibitors 0.68 (0.39-1.22) .2
Aspirin 0.45 (0.26-0.79) .003
Statins 1.06 (0.60-1.85) .8
Serum creatinine 1.34 (0.82-2.17) .09
FEV1 0.54 (0.22-1.36) .12
FVC 0.81 (0.49-1.33) .3
% Predicted FVC 1.01 (0.99-1.04) .3
FEV1/FVC ratio 0.31 (0.17-0.57) .02
LV ejection fraction 1.00 (0.98-1.02) .9
Left atrial area 1.13 (0.74-1.72) .6
LV end-systolic dimension 0.88 (0.58-1.34) .5
Mitral regurgitation 1.04 (0.82-1.32) .7
Aortic regurgitation 1.08 (0.84-1.40) .5
Tricuspid regurgitation 1.15 (0.89-1.49) .3
Right ventricular systolic pressure 1.01 (0.99-1.03) .2
Diastolic dysfunction 1.03 (0.73-1.45) .9
Mitral valve splitability score 0.99 (0.92-1.07) .8
Aortic valve dimensionless index 0.11 (0.02-0.50) <.001
PF score on MDCT 1.11 (1.02-1.20) .02
Ascending aortic calcification on MDCT 1.07 (0.84-1.37) .6
Postoperative findings
LV ejection fraction 1.02 (0.0.99-1.04) .12
Mitral regurgitation 1.12 (0.67-1.88) .7
Aortic regurgitation 1.51 (0.59-3.86) .3
Tricuspid regurgitation 1.003 (0.75-1.35) .9
Right ventricular systolic pressure 1.01 (0.97-1.06) .4
Right ventricular dysfunction 0.95 (0.50-1.80) .9
Permanent atrial fibrillation 0.66 (0.27-1.62) .3
Bold values represent P values that are significant (<.05). ACE, Angiotensin-
converting enzyme; CI, confidence interval; euroSCORE, European System for Car-
diac Operative Risk Evaluation; LV, left ventricular; FEV1, forced expiratory volume
in 1 second; FVC, forced vital capacity;MDCT,multidetector chest computed tomog-
raphy; PF, pulmonary fibrosis.
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